

Sensitivity Analyses

Supplemental Analysis: Inclusion of Emerging Treatments — Efficacy and Harms Treatment-Naive

TABLE 157: GENOTYPE 1 TREATMENT-NAIVE WITH EMERGING TREATMENTS: RELATIVE RISK AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	1.47 (1.01 to 1.77)	25.16 (0.41 to 39.13)
SIM12 + SOF12		1.70 (0.85 to 1.95)	37.61 (−7.71 to 47.57)
SOF12 + LDV12		1.81 (1.66 to 1.98)	43.04 (38.00 to 47.99)
SOF8 + LDV8 + RBV8		1.76 (1.54 to 1.94)	40.47 (29.71 to 46.71)
SOF12 + LDV12 + RBV12		1.77 (1.61 to 1.95)	41.04 (34.39 to 46.85)
SOF24 + LDV24 + RBV24		1.83 (1.67 to 2.01)	44.26 (38.20 to 49.34)
T12 PR24-48 RGT q8		1.52 (1.34 to 1.68)	27.77 (18.64 to 34.53)
T12 PR24-48 RGT q12		1.54 (1.31 to 1.73)	28.81 (16.38 to 37.01)
T12 PR48 q8		1.50 (0.97 to 1.87)	26.55 (−1.92 to 43.18)
SOF12 + PR12		1.56 (1.20 to 1.79)	29.68 (10.50 to 40.19)
SOF12 PR24-48 RGT		1.63 (1.24 to 1.87)	33.97 (13.15 to 43.97)
SIM12 PR24-48 RGT		1.49 (1.33 to 1.66)	26.14 (18.17 to 32.99)
B24 PR28-48 RGT		1.43 (1.25 to 1.60)	23.04 (13.35 to 30.89)
B44 PR48		1.53 (1.19 to 1.79)	28.58 (10.50 to 40.12)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV (low dose) 24		0.86 (0.43 to 1.36)	-7.33 (-30.59 to 18.75)
SOF12+ SIM12+ RBV12		1.73 (0.60 to 1.98)	39.59 (-21.34 to 48.81)
SOF12 + RBV12		1.56 (0.95 to 1.88)	30.18 (-2.79 to 44.55)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.80 (1.65 to 1.98)	42.88 (36.87 to 48.06)
DCV24 + ASU24		1.63 (1.43 to 1.82)	33.45 (23.72 to 40.78)
DCV12 + SOF12		1.78 (1.31 to 2.01)	41.88 (16.78 to 49.42)
PAR/RIT12 + OMB12 + DAS12		1.81 (1.37 to 2.01)	43.82 (19.92 to 49.59)
GRZ12 + ELB12		1.75 (1.54 to 1.94)	40.03 (30.15 to 46.48)
GRZ12 + ELB12 + RBV12		1.66 (1.08 to 1.93)	35.12 (4.21 to 46.17)
DCV12 + ASU12 + BEC12 + RBV12		1.80 (1.53 to 2.00)	42.97 (28.89 to 49.25)
DCV12 + ASU12 + BEC12		1.73 (1.58 to 1.91)	39.17 (32.61 to 44.59)
GRZ12 + ELB12 (50 mg q.d.)		1.74 (1.27 to 1.98)	39.45 (14.76 to 48.06)
GRZ18 + ELB18 (50 mg q.d.)		1.72 (0.98 to 1.97)	38.62 (-0.96 to 48.01)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.00 (0.00 to 1.95)	-0.27 (-54.43 to 48.03)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.74 (1.12 to 1.97)	39.77 (6.45 to 48.24)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.78 (1.17 to 2.01)	41.99 (9.12 to 49.42)
SIM12 + SOF12	SOF24 + RBV24	1.15 (0.59 to 1.69)	11.81 (-32.06 to 37.96)
SOF12 + LDV12		1.23 (1.05 to 1.79)	17.81 (4.73 to 42.49)
SOF8 + LDV8 + RBV8		1.19 (0.99 to 1.75)	15.06 (-1.29 to 40.23)
SOF12 + LDV12 + RBV12		1.20 (1.03 to 1.74)	16.09 (2.35 to 39.83)
SOF24 + LDV24 + RBV24		1.24 (1.06 to 1.82)	19.06 (5.77 to 43.78)
T12 PR24-48 RGT q8		1.03 (0.85 to 1.52)	2.63 (-13.69 to 28.17)
T12 PR24-48 RGT q12		1.05 (0.83 to 1.56)	3.56 (-14.80 to 30.14)
T12 PR48 q8		1.02 (0.67 to 1.55)	1.50 (-28.17 to 30.43)
SOF12 + PR12		1.06 (0.79 to 1.56)	4.49 (-18.50 to 30.72)
SOF12 PR24-48 RGT		1.11 (0.81 to 1.64)	8.41 (-16.82 to 35.04)
SIM12 PR24-48 RGT		1.01 (0.84 to 1.51)	1.09 (-14.63 to 27.37)
B24 PR28-48 RGT		0.98 (0.79 to 1.43)	-1.97 (-18.79 to 23.66)
B44 PR48		1.04 (0.78 to 1.57)	3.04 (-19.03 to 30.90)
SOF24 + RBV (low dose) 24		0.60 (0.38 to 0.81)	-30.26 (-43.74 to -16.33)
SOF12 + SIM12 + RBV12		1.16 (0.40 to 1.76)	12.87 (-49.34 to 41.90)
SOF12 + RBV12		1.06 (0.72 to 1.44)	4.64 (-21.72 to 26.36)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.23 (1.05 to 1.80)	17.73 (4.18 to 42.62)
DCV24 + ASU24		1.10 (0.90 to 1.64)	8.17 (-8.74 to 34.51)
DCV12 + SOF12		1.20 (0.89 to 1.78)	15.48 (-8.94 to 42.23)
PAR/RIT12 + OMB12 + DAS12		1.23 (0.93 to 1.79)	17.87 (-5.61 to 42.85)
GRZ12 + ELB12		1.18 (0.99 to 1.75)	14.54 (-1.15 to 40.50)
GRZ12 + ELB12 + RBV12		1.11 (0.73 to 1.71)	8.98 (-22.68 to 38.40)
DCV12 + ASU12 + BEC12 + RBV12		1.22 (1.00 to 1.80)	17.27 (-0.17 to 43.29)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV12 + ASU12 + BEC12		1.18 (1.00 to 1.74)	13.89 (-0.17 to 39.49)
GRZ12 + ELB12 (50 mg q.d.)		1.17 (0.85 to 1.78)	13.23 (-12.25 to 42.10)
GRZ18 + ELB18 (50 mg q.d.)		1.15 (0.68 to 1.76)	11.93 (-25.60 to 41.56)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.69 (0.00 to 1.57)	-24.09 (-85.28 to 34.50)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.17 (0.77 to 1.76)	13.48 (-18.62 to 40.96)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.19 (0.81 to 1.81)	15.08 (-15.60 to 43.70)
SOF12 + LDV12	SIM12 + SOF12	1.06 (0.97 to 2.13)	5.16 (-2.81 to 50.60)
SOF8 + LDV8 + RBV8		1.03 (0.90 to 2.08)	2.43 (-9.15 to 47.92)
SOF12 + LDV12 + RBV12		1.03 (0.93 to 2.09)	3.15 (-6.72 to 48.93)
SOF24 + LDV24 + RBV24		1.07 (0.97 to 2.16)	6.27 (-2.52 to 52.09)
T12 PR24-48 RGT q8		0.89 (0.76 to 1.77)	-9.78 (-22.97 to 35.28)
T12 PR24-48 RGT q12		0.91 (0.75 to 1.80)	-8.74 (-24.18 to 36.03)
T12 PR48 q8		0.89 (0.57 to 1.83)	-10.48 (-41.77 to 38.37)
SOF12 + PR12		0.92 (0.73 to 1.66)	-7.49 (-24.54 to 30.49)
SOF12 PR24-48 RGT		0.96 (0.74 to 1.85)	-3.75 (-24.44 to 38.57)
SIM12 PR24-48 RGT		0.88 (0.76 to 1.77)	-11.44 (-23.56 to 34.73)
B24 PR28-48 RGT		0.84 (0.71 to 1.70)	-14.33 (-27.90 to 31.22)
B44 PR48		0.91 (0.70 to 1.76)	-8.28 (-28.36 to 34.88)
SOF24 + RBV (low dose) 24		0.53 (0.25 to 1.10)	-42.37 (-69.14 to 5.06)
SOF12 + SIM12 + RBV12		1.01 (0.41 to 1.67)	1.23 (-49.59 to 33.19)
SOF12 + RBV12		0.93 (0.55 to 1.76)	-6.19 (-41.92 to 34.45)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.06 (0.96 to 2.13)	5.08 (-3.67 to 50.71)
DCV24 + ASU24		0.95 (0.82 to 1.92)	-4.40 (-17.07 to 41.97)
DCV12 + SOF12		1.04 (0.76 to 2.10)	3.65 (-22.84 to 49.76)
PAR/RIT12 + OMB12 + DAS12		1.06 (0.79 to 2.15)	5.27 (-20.03 to 52.12)
GRZ12 + ELB12		1.02 (0.90 to 2.07)	2.14 (-9.95 to 48.23)
GRZ12 + ELB12 + RBV12		0.97 (0.65 to 2.02)	-2.42 (-32.61 to 45.94)
DCV12 + ASU12 + BEC12 + RBV12		1.06 (0.87 to 2.14)	5.16 (-12.88 to 51.10)
DCV12 + ASU12 + BEC12		1.02 (0.91 to 2.06)	1.40 (-9.03 to 47.77)
GRZ12 + ELB12 (50 mg q.d.)		1.02 (0.75 to 2.09)	1.55 (-23.25 to 49.33)
GRZ18 + ELB18 (50 mg q.d.)		1.00 (0.59 to 2.06)	0.24 (-38.42 to 48.33)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.61 (0.00 to 1.50)	-33.45 (-95.72 to 30.08)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.02 (0.70 to 2.10)	1.39 (-27.30 to 49.31)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.04 (0.68 to 2.11)	3.83 (-30.92 to 50.48)
SOF8 + LDV8 + RBV8	SOF12 + LDV12	0.98 (0.88 to 1.01)	-2.34 (-11.61 to 1.01)
SOF12 + LDV12 + RBV12		0.98 (0.92 to 1.02)	-1.89 (-7.25 to 1.77)
SOF24 + LDV24 + RBV24		1.01 (0.97 to 1.05)	1.24 (-3.27 to 4.62)
T12 PR24-48 RGT q8		0.84 (0.74 to 0.91)	-15.25 (-25.00 to -8.24)
T12 PR24-48 RGT q12		0.85 (0.72 to 0.93)	-14.12 (-27.03 to -6.23)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
T12 PR48 q8		0.83 (0.55 to 0.99)	-16.59 (-43.80 to -1.43)
SOF12 + PR12		0.86 (0.67 to 0.95)	-13.35 (-30.91 to -5.04)
SOF12 PR24-48 RGT		0.90 (0.70 to 1.00)	-9.23 (-29.29 to 0.24)
SIM12 PR24-48 RGT		0.83 (0.75 to 0.89)	-16.85 (-24.76 to -10.31)
B24 PR28-48 RGT		0.79 (0.69 to 0.88)	-19.96 (-30.40 to -11.58)
B44 PR48		0.85 (0.67 to 0.96)	-14.42 (-32.11 to -3.87)
SOF24 + RBV (low dose) 24		0.48 (0.23 to 0.74)	-50.17 (-73.36 to -24.70)
SOF12 + SIM12 + RBV12		0.97 (0.33 to 1.05)	-3.18 (-64.28 to 4.25)
SOF12 + RBV12		0.87 (0.52 to 1.01)	-12.75 (-46.13 to 0.93)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.00 (0.96 to 1.03)	-0.12 (-3.85 to 2.46)
DCV24 + ASU24		0.90 (0.80 to 0.97)	-9.56 (-19.05 to -2.83)
DCV12 + SOF12		0.99 (0.74 to 1.06)	-1.00 (-25.26 to 5.28)
PAR/RIT12 + OMB12 + DAS12		1.01 (0.76 to 1.06)	1.08 (-22.74 to 5.15)
GRZ12 + ELB12		0.97 (0.87 to 1.03)	-2.88 (-12.22 to 2.54)
GRZ12 + ELB12 + RBV12		0.92 (0.61 to 1.02)	-7.83 (-37.91 to 1.57)
DCV12 + ASU12 + BEC12 + RBV12		1.00 (0.85 to 1.05)	0.31 (-14.28 to 4.78)
DCV12 + ASU12 + BEC12		0.96 (0.90 to 1.01)	-3.80 (-10.14 to 0.70)
GRZ12 + ELB12 (50 mg q.d.)		0.97 (0.72 to 1.04)	-3.33 (-27.04 to 3.31)
GRZ18 + ELB18 (50 mg q.d.)		0.96 (0.55 to 1.04)	-4.24 (-43.16 to 3.91)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.55 (0.00 to 1.04)	-43.34 (-96.70 to 3.96)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.97 (0.63 to 1.04)	-2.91 (-35.36 to 3.89)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.99 (0.65 to 1.05)	-0.68 (-34.07 to 4.76)
SOF12 + LDV12 + RBV12	SOF8 + LDV8 + RBV8	1.01 (0.94 to 1.13)	0.52 (-5.51 to 10.53)
SOF24 + LDV24 + RBV24		1.04 (0.98 to 1.18)	3.57 (-2.04 to 14.52)
T12 PR24-48 RGT q8		0.87 (0.76 to 0.99)	-12.68 (-23.07 to -0.88)
T12 PR24-48 RGT q12		0.88 (0.74 to 1.01)	-11.48 (-24.95 to 1.03)
T12 PR48 q8		0.85 (0.56 to 1.05)	-13.76 (-41.23 to 4.08)
SOF12 + PR12		0.89 (0.70 to 1.00)	-10.52 (-28.07 to -0.32)
SOF12 PR24-48 RGT		0.93 (0.72 to 1.09)	-6.69 (-27.02 to 7.52)
SIM12 PR24-48 RGT		0.85 (0.76 to 0.97)	-14.22 (-23.17 to -2.99)
B24 PR28-48 RGT		0.82 (0.70 to 0.95)	-17.28 (-28.46 to -4.61)
B44 PR48		0.88 (0.68 to 1.02)	-11.68 (-30.05 to 1.95)
SOF24 + RBV (low dose 24		0.50 (0.24 to 0.78)	-46.86 (-70.99 to -20.18)
SOF12 + SIM12 + RBV12		0.99 (0.34 to 1.13)	-0.50 (-61.96 to 11.50)
SOF12 + RBV12		0.89 (0.54 to 1.09)	-10.12 (-43.47 to 7.72)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.02 (0.97 to 1.14)	2.16 (-2.63 to 12.02)
DCV24 + ASU24		0.93 (0.82 to 1.05)	-7.03 (-17.28 to 4.35)
DCV12 + SOF12		1.01 (0.76 to 1.17)	1.21 (-22.86 to 13.86)
PAR/RIT12 + OMB12 + DAS12		1.03 (0.79 to 1.17)	3.21 (-20.34 to 14.52)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12		0.99 (0.89 to 1.14)	-0.57 (-10.33 to 11.45)
GRZ12 + ELB12 + RBV12		0.95 (0.63 to 1.10)	-5.15 (-35.30 to 8.39)
DCV12 + ASU12 + BEC12 + RBV12		1.03 (0.86 to 1.16)	2.49 (-12.94 to 13.55)
DCV12 + ASU12 + BEC12		0.99 (0.91 to 1.12)	-1.30 (-8.64 to 9.85)
GRZ12 + ELB12 (50 mg q.d.)		0.99 (0.74 to 1.14)	-0.74 (-25.31 to 11.48)
GRZ18 + ELB18 (50 mg q.d.)		0.98 (0.57 to 1.14)	-1.69 (-40.63 to 11.90)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.57 (0.00 to 1.11)	-40.07 (-95.28 to 9.32)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.00 (0.65 to 1.14)	-0.46 (-33.09 to 11.62)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.02 (0.66 to 1.15)	1.63 (-32.16 to 13.04)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.03 (0.98 to 1.10)	3.05 (-1.89 to 8.84)
T12 PR24-48 RGT q8		0.86 (0.76 to 0.95)	-13.29 (-23.23 to -4.63)
T12 PR24-48 RGT q12		0.87 (0.73 to 0.97)	-12.21 (-25.40 to -2.78)
T12 PR48 q8		0.85 (0.56 to 1.01)	-14.45 (-42.11 to 1.31)
SOF12 + PR12		0.88 (0.68 to 0.99)	-11.20 (-30.30 to -1.36)
SOF12 PR24-48 RGT		0.92 (0.71 to 1.04)	-7.20 (-27.19 to 3.56)
SIM12 PR24-48 RGT		0.84 (0.76 to 0.92)	-14.80 (-23.40 to -7.22)
B24 PR28-48 RGT		0.81 (0.70 to 0.91)	-17.97 (-28.73 to -8.56)
B44 PR48		0.87 (0.68 to 0.99)	-12.41 (-30.43 to -0.71)
SOF24 + RBV (low dose) 24		0.49 (0.24 to 0.76)	-48.12 (-70.76 to -22.79)
SOF12 + SIM12 + RBV12		0.98 (0.34 to 1.09)	-1.52 (-62.71 to 8.12)
SOF12 + RBV12		0.89 (0.53 to 1.04)	-10.66 (-43.82 to 3.81)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.02 (0.97 to 1.08)	1.72 (-3.28 to 7.35)
DCV24 + ASU24		0.92 (0.82 to 1.00)	-7.55 (-17.38 to 0.27)
DCV12 + SOF12		1.01 (0.75 to 1.10)	0.79 (-23.29 to 8.97)
PAR/RIT12 + OMB12 + DAS12		1.03 (0.79 to 1.10)	2.77 (-20.03 to 9.26)
GRZ12 + ELB12		0.99 (0.89 to 1.07)	-0.95 (-10.87 to 6.15)
GRZ12 + ELB12 + RBV12		0.94 (0.62 to 1.06)	-5.95 (-36.23 to 5.42)
DCV12 + ASU12 + BEC12 + RBV12		1.02 (0.87 to 1.10)	2.04 (-12.31 to 8.68)
DCV12 + ASU12 + BEC12		0.98 (0.91 to 1.05)	-1.92 (-8.75 to 4.74)
GRZ12 + ELB12 (50 mg q.d.)		0.99 (0.74 to 1.08)	-1.28 (-25.26 to 7.10)
GRZ18 + ELB18 (50 mg q.d.)		0.98 (0.56 to 1.08)	-1.91 (-41.86 to 7.12)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.56 (0.00 to 1.08)	-41.17 (-95.46 to 7.08)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.99 (0.64 to 1.08)	-1.04 (-34.31 to 7.15)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.01 (0.66 to 1.10)	1.08 (-32.19 to 8.53)
T12 PR24-48 RGT q8	SOF24 + LDV24 + RBV24	0.83 (0.73 to 0.91)	-16.47 (-26.04 to -8.84)
T12 PR24-48 RGT q12		0.84 (0.71 to 0.93)	-15.34 (-27.96 to -6.79)
T12 PR48 q8		0.82 (0.54 to 0.98)	-17.59 (-44.78 to -2.32)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + PR12		0.85 (0.65 to 0.95)	-14.48 (-34.06 to -4.35)
SOF12 PR24-48 RGT		0.90 (0.69 to 0.99)	-10.21 (-30.54 to -0.65)
SIM12 PR24-48 RGT		0.82 (0.74 to 0.88)	-17.98 (-25.94 to -11.08)
B24 PR28-48 RGT		0.78 (0.68 to 0.87)	-21.15 (-31.52 to -12.30)
B44 PR48		0.84 (0.66 to 0.95)	-15.51 (-33.48 to -4.91)
SOF24 + RBV (low dose) 24		0.47 (0.23 to 0.74)	-51.26 (-74.55 to -25.90)
SOF12 + SIM12 + RBV12		0.96 (0.33 to 1.04)	-4.22 (-65.76 to 3.97)
SOF12 + RBV12		0.86 (0.51 to 1.00)	-13.76 (-47.36 to -0.35)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.99 (0.94 to 1.04)	-1.35 (-6.22 to 3.30)
DCV24 + ASU24		0.89 (0.79 to 0.96)	-10.73 (-20.20 to -3.42)
DCV12 + SOF12		0.98 (0.73 to 1.05)	-2.05 (-26.73 to 4.38)
PAR/RIT12 + OMB12 + DAS12		1.00 (0.77 to 1.03)	-0.19 (-21.52 to 3.16)
GRZ12 + ELB12		0.96 (0.86 to 1.02)	-4.00 (-13.40 to 1.56)
GRZ12 + ELB12 + RBV12		0.91 (0.60 to 1.01)	-9.10 (-38.91 to 0.79)
DCV12 + ASU12 + BEC12 + RBV12		0.99 (0.85 to 1.04)	-0.84 (-14.81 to 4.09)
DCV12 + ASU12 + BEC12		0.95 (0.89 to 1.00)	-5.00 (-11.30 to 0.35)
GRZ12 + ELB12 (50 mg q.d.)		0.95 (0.71 to 1.03)	-4.58 (-28.30 to 3.11)
GRZ18 + ELB18 (50 mg q.d.)		0.95 (0.55 to 1.03)	-5.33 (-44.19 to 3.23)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.54 (0.00 to 1.03)	-44.40 (-98.04 to 3.05)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.96 (0.63 to 1.03)	-4.14 (-36.26 to 3.23)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.98 (0.64 to 1.05)	-2.00 (-34.66 to 4.49)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	1.01 (0.92 to 1.09)	1.11 (-6.50 to 6.74)
T12 PR48 q8		0.98 (0.64 to 1.23)	-1.29 (-30.44 to 17.47)
SOF12 + PR12		1.02 (0.78 to 1.20)	1.88 (-17.91 to 15.19)
SOF12 PR24-48 RGT		1.08 (0.83 to 1.26)	6.09 (-14.53 to 19.33)
SIM12 PR24-48 RGT		0.98 (0.87 to 1.12)	-1.45 (-11.30 to 8.93)
B24 PR28-48 RGT		0.94 (0.81 to 1.10)	-4.70 (-15.93 to 7.21)
B44 PR48		1.01 (0.78 to 1.20)	0.80 (-17.79 to 14.95)
SOF24 + RBV (low dose) 24		0.57 (0.28 to 0.90)	-34.49 (-59.34 to -7.57)
SOF12 + SIM12 + RBV12		1.14 (0.39 to 1.33)	11.79 (-49.93 to 24.07)
SOF12 + RBV12		1.03 (0.61 to 1.25)	2.60 (-31.89 to 18.88)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.19 (1.08 to 1.35)	15.03 (7.27 to 25.04)
DCV24 + ASU24		1.07 (0.93 to 1.23)	5.74 (-5.58 to 16.43)
DCV12 + SOF12		1.17 (0.86 to 1.35)	13.78 (-11.40 to 25.34)
PAR/RIT12 + OMB12 + DAS12		1.19 (0.91 to 1.36)	15.81 (-7.79 to 25.66)
GRZ12 + ELB12		1.15 (1.01 to 1.32)	12.21 (1.07 to 22.91)
GRZ12 + ELB12 + RBV12		1.09 (0.72 to 1.29)	7.24 (-23.56 to 20.92)
DCV12 + ASU12 + BEC12 + RBV12		1.18 (1.01 to 1.36)	14.95 (0.96 to 25.69)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV12 + ASU12 + BEC12		1.14 (1.04 to 1.29)	11.36 (3.21 to 21.25)
GRZ12 + ELB12 (50 mg q.d.)		1.14 (0.85 to 1.32)	11.66 (-12.35 to 23.29)
GRZ18 + ELB18 (50 mg q.d.)		1.13 (0.65 to 1.32)	10.43 (-28.61 to 23.27)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.66 (0.00 to 1.29)	-27.71 (-83.26 to 22.29)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.14 (0.76 to 1.33)	11.80 (-19.82 to 23.88)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.17 (0.76 to 1.35)	13.86 (-19.44 to 25.12)
T12 PR48 q8	T12 PR24-48 RGT q12	0.97 (0.63 to 1.25)	-2.34 (-31.60 to 18.31)
SOF12 + PR12		1.01 (0.77 to 1.23)	0.91 (-19.36 to 16.38)
SOF12 PR24-48 RGT		1.06 (0.81 to 1.29)	4.98 (-16.15 to 20.56)
SIM12 PR24-48 RGT		0.97 (0.85 to 1.15)	-2.48 (-13.46 to 10.37)
B24 PR28-48 RGT		0.93 (0.79 to 1.12)	-5.70 (-17.80 to 8.62)
B44 PR48		1.00 (0.77 to 1.23)	-0.17 (-19.11 to 16.22)
SOF24 + RBV (low dose) 24		0.57 (0.27 to 0.91)	-35.22 (-60.98 to -7.18)
SOF12 + SIM12 + RBV12		1.13 (0.39 to 1.35)	10.55 (-51.27 to 25.31)
SOF12 + RBV12		1.02 (0.60 to 1.27)	1.52 (-32.97 to 19.71)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.17 (1.06 to 1.39)	13.91 (5.31 to 26.97)
DCV24 + ASU24		1.06 (0.92 to 1.25)	4.66 (-7.26 to 17.70)
DCV12 + SOF12		1.15 (0.85 to 1.38)	12.52 (-12.39 to 26.88)
PAR/RIT12 + OMB12 + DAS12		1.18 (0.89 to 1.39)	14.61 (-9.31 to 27.46)
GRZ12 + ELB12		1.13 (0.99 to 1.35)	10.97 (-0.61 to 24.68)
GRZ12 + ELB12 + RBV12		1.07 (0.71 to 1.31)	5.93 (-24.56 to 22.04)
DCV12 + ASU12 + BEC12 + RBV12		1.17 (0.99 to 1.39)	13.87 (-0.66 to 27.52)
DCV12 + ASU12 + BEC12		1.13 (1.01 to 1.33)	10.26 (0.94 to 23.32)
GRZ12 + ELB12 (50 mg q.d.)		1.13 (0.84 to 1.35)	10.43 (-13.05 to 24.76)
GRZ18 + ELB18 (50 mg q.d.)		1.11 (0.65 to 1.35)	9.23 (-29.61 to 24.72)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.65 (0.00 to 1.30)	-28.62 (-84.95 to 22.52)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.13 (0.75 to 1.36)	10.57 (-21.22 to 25.44)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.15 (0.75 to 1.38)	12.63 (-20.88 to 26.93)
SOF12 + PR12	T12 PR48 q8	1.04 (0.73 to 1.59)	3.07 (-23.91 to 32.00)
SOF12 PR24-48 RGT		1.08 (0.80 to 1.71)	6.64 (-17.78 to 38.41)
SIM12 PR24-48 RGT		1.00 (0.81 to 1.52)	-0.35 (-17.92 to 27.54)
B24 PR28-48 RGT		0.96 (0.76 to 1.47)	-3.29 (-22.32 to 25.21)
B44 PR48		1.03 (0.75 to 1.59)	2.09 (-21.88 to 31.80)
SOF24 + RBV (low dose) 24		0.60 (0.27 to 1.09)	-31.97 (-62.65 to 5.60)
SOF12 + SIM12 + RBV12		1.15 (0.39 to 1.79)	11.81 (-49.80 to 43.02)
SOF12 + RBV12		1.04 (0.61 to 1.64)	3.48 (-34.46 to 35.28)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.21 (1.01 to 1.81)	16.45 (0.88 to 43.10)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV24 + ASU24		1.08 (0.88 to 1.65)	6.73 (-11.10 to 34.22)
DCV12 + SOF12		1.17 (0.94 to 1.69)	13.78 (-4.70 to 38.11)
PAR/RIT12 + OMB12 + DAS12		1.21 (0.87 to 1.83)	16.74 (-11.69 to 44.13)
GRZ12 + ELB12		1.17 (0.96 to 1.77)	13.27 (-4.07 to 41.35)
GRZ12 + ELB12 + RBV12		1.10 (0.69 to 1.73)	7.95 (-26.50 to 39.28)
DCV12 + ASU12 + BEC12 + RBV12		1.20 (0.97 to 1.83)	15.85 (-2.39 to 44.25)
DCV12 + ASU12 + BEC12		1.16 (0.97 to 1.75)	12.66 (-3.10 to 40.10)
GRZ12 + ELB12 (50 mg q.d.)		1.15 (0.84 to 1.80)	12.13 (-14.37 to 42.87)
GRZ18 + ELB18 (50 mg q.d.)		1.13 (0.66 to 1.77)	10.67 (-28.45 to 41.31)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.68 (0.00 to 1.57)	-25.06 (-87.83 to 34.55)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.15 (0.77 to 1.78)	12.27 (-19.20 to 41.86)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.17 (0.78 to 1.81)	13.99 (-18.15 to 43.73)
SOF12 PR24-48 RGT	SOF12 + PR12	1.05 (0.80 to 1.38)	4.06 (-17.70 to 24.74)
SIM12 PR24-48 RGT		0.96 (0.83 to 1.26)	-3.65 (-15.84 to 16.35)
B24 PR28-48 RGT		0.92 (0.77 to 1.22)	-6.63 (-20.63 to 14.06)
B44 PR48		0.99 (0.76 to 1.31)	-0.99 (-20.45 to 20.06)
SOF24 + RBV (low dose) 24		0.56 (0.28 to 0.91)	-35.83 (-61.71 to -6.25)
SOF12 + SIM12 + RBV12		1.11 (0.39 to 1.41)	9.05 (-51.25 to 27.66)
SOF12 + RBV12		1.00 (0.61 to 1.38)	0.28 (-33.50 to 24.83)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.16 (1.05 to 1.48)	13.05 (4.38 to 30.83)
DCV24 + ASU24		1.04 (0.89 to 1.37)	3.54 (-9.55 to 23.54)
DCV12 + SOF12		1.14 (0.84 to 1.52)	11.42 (-14.29 to 32.93)
PAR/RIT12 + OMB12 + DAS12		1.16 (0.89 to 1.52)	13.45 (-9.28 to 33.60)
GRZ12 + ELB12		1.12 (0.97 to 1.47)	10.13 (-2.57 to 30.06)
GRZ12 + ELB12 + RBV12		1.07 (0.70 to 1.41)	5.52 (-25.98 to 26.94)
DCV12 + ASU12 + BEC12 + RBV12		1.16 (0.95 to 1.51)	13.00 (-4.58 to 32.77)
DCV12 + ASU12 + BEC12		1.12 (0.98 to 1.46)	9.55 (-1.95 to 29.21)
GRZ12 + ELB12 (50 mg q.d.)		1.11 (0.82 to 1.47)	9.43 (-16.06 to 30.29)
GRZ18 + ELB18 (50 mg q.d.)		1.10 (0.64 to 1.46)	8.12 (-30.66 to 30.23)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.65 (0.00 to 1.37)	-28.52 (-87.81 to 25.97)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.11 (0.74 to 1.48)	9.25 (-22.35 to 31.21)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.14 (0.73 to 1.51)	11.57 (-22.98 to 32.36)
SIM12 PR24-48 RGT	SOF12 PR24-48 RGT	0.91 (0.79 to 1.19)	-7.56 (-20.01 to 13.18)
B24 PR28-48 RGT		0.88 (0.74 to 1.16)	-10.79 (-24.41 to 10.85)
B44 PR48		0.95 (0.72 to 1.24)	-4.79 (-25.55 to 16.52)
SOF24 + RBV (low dose) 24		0.54 (0.26 to 0.90)	-39.76 (-66.75 to -7.32)
SOF12 + SIM12 + RBV12		1.06 (0.37 to 1.37)	5.12 (-54.80 to 26.29)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12		0.96 (0.57 to 1.32)	-3.44 (-37.66 to 22.23)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.10 (0.99 to 1.43)	8.96 (-1.10 to 29.04)
DCV24 + ASU24		1.00 (0.85 to 1.30)	-0.32 (-13.77 to 20.05)
DCV12 + SOF12		1.08 (0.80 to 1.40)	7.45 (-17.99 to 27.75)
PAR/RIT12 + OMB12 + DAS12		1.11 (0.85 to 1.44)	9.53 (-13.73 to 30.07)
GRZ12 + ELB12		1.07 (0.93 to 1.40)	5.85 (-6.36 to 27.30)
GRZ12 + ELB12 + RBV12		1.02 (0.67 to 1.34)	1.46 (-29.20 to 23.32)
DCV12 + ASU12 + BEC12 + RBV12		1.10 (0.93 to 1.42)	8.76 (-6.64 to 28.80)
DCV12 + ASU12 + BEC12		1.06 (0.94 to 1.38)	5.22 (-5.30 to 25.49)
GRZ12 + ELB12 (50 mg q.d.)		1.06 (0.79 to 1.39)	5.28 (-18.53 to 26.53)
GRZ18 + ELB18 (50 mg q.d.)		1.05 (0.61 to 1.38)	4.04 (-34.05 to 26.48)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.62 (0.00 to 1.31)	-33.03 (-91.64 to 22.75)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.06 (0.71 to 1.38)	5.26 (-25.84 to 26.34)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.08 (0.73 to 1.40)	7.46 (-23.96 to 27.49)
B24 PR28-48 RGT	SIM12 PR24-48 RGT	0.96 (0.83 to 1.10)	-3.11 (-14.32 to 7.75)
B44 PR48		1.03 (0.80 to 1.21)	2.47 (-15.98 to 15.49)
SOF24 + RBV (low dose) 24		0.58 (0.28 to 0.92)	-33.25 (-58.26 to -6.52)
SOF12 + SIM12 + RBV12		1.17 (0.41 to 1.34)	13.36 (-47.56 to 24.93)
SOF12 + RBV12		1.05 (0.62 to 1.26)	4.16 (-30.44 to 19.86)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.21 (1.11 to 1.34)	16.64 (9.55 to 24.70)
DCV24 + ASU24		1.09 (1.01 to 1.18)	7.21 (0.79 to 13.15)
DCV12 + SOF12		1.19 (0.89 to 1.35)	15.58 (-8.98 to 25.29)
PAR/RIT12 + OMB12 + DAS12		1.22 (0.92 to 1.36)	17.50 (-6.08 to 25.82)
GRZ12 + ELB12		1.17 (1.04 to 1.31)	13.77 (2.99 to 22.81)
GRZ12 + ELB12 + RBV12		1.11 (0.73 to 1.30)	8.72 (-21.61 to 22.03)
DCV12 + ASU12 + BEC12 + RBV12		1.21 (1.03 to 1.35)	16.76 (2.11 to 25.43)
DCV12 + ASU12 + BEC12		1.16 (1.06 to 1.29)	12.95 (5.32 to 21.31)
GRZ12 + ELB12 (50 mg q.d.)		1.17 (0.86 to 1.33)	13.25 (-11.08 to 23.84)
GRZ18 + ELB18 (50 mg q.d.)		1.15 (0.67 to 1.32)	12.37 (-26.26 to 23.54)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.67 (0.00 to 1.30)	-26.40 (-81.33 to 22.96)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.17 (0.76 to 1.33)	13.37 (-19.20 to 24.19)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.19 (0.78 to 1.35)	15.54 (-18.30 to 25.30)
B44 PR48	B24 PR28-48 RGT	1.07 (0.83 to 1.30)	5.47 (-13.85 to 20.55)
SOF24 + RBV (low dose) 24		0.61 (0.29 to 0.97)	-30.04 (-54.68 to -2.42)
SOF12 + SIM12 + RBV12		1.21 (0.42 to 1.43)	16.14 (-45.32 to 29.35)
SOF12 + RBV12		1.09 (0.66 to 1.35)	7.18 (-26.46 to 24.22)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.26 (1.13 to 1.46)	19.73 (10.93 to 30.47)
DCV24 + ASU24		1.14 (0.98 to 1.32)	10.47 (-1.70 to 21.62)
DCV12 + SOF12		1.24 (0.92 to 1.46)	18.29 (-6.35 to 30.72)
PAR/RIT12 + OMB12 + DAS12		1.27 (0.96 to 1.47)	20.49 (-3.41 to 31.27)
GRZ12 + ELB12		1.22 (1.06 to 1.42)	16.87 (5.15 to 27.99)
GRZ12 + ELB12 + RBV12		1.15 (0.76 to 1.39)	11.78 (-19.04 to 26.22)
DCV12 + ASU12 + BEC12 + RBV12		1.26 (1.06 to 1.46)	19.64 (4.74 to 30.69)
DCV12 + ASU12 + BEC12		1.21 (1.08 to 1.40)	16.08 (6.77 to 26.57)
GRZ12 + ELB12 (50 mg q.d.)		1.21 (0.89 to 1.43)	16.11 (-8.53 to 28.77)
GRZ18 + ELB18 (50 mg q.d.)		1.20 (0.69 to 1.42)	15.16 (-24.00 to 28.73)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.69 (0.00 to 1.38)	-23.25 (-79.11 to 27.20)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.21 (0.79 to 1.43)	16.30 (-16.28 to 29.08)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.24 (0.81 to 1.45)	18.42 (-14.81 to 30.48)
SOF24 + RBV (low dose) 24	B44 PR48	0.58 (0.27 to 0.94)	-34.12 (-62.76 to -4.10)
SOF12 + SIM12 + RBV12		1.12 (0.40 to 1.45)	10.09 (-50.09 to 29.91)
SOF12 + RBV12		1.02 (0.60 to 1.35)	1.71 (-33.34 to 23.98)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.17 (1.04 to 1.50)	14.21 (3.31 to 32.11)
DCV24 + ASU24		1.06 (0.90 to 1.36)	4.81 (-8.96 to 23.14)
DCV12 + SOF12		1.15 (0.85 to 1.50)	12.43 (-12.69 to 32.47)
PAR/RIT12 + OMB12 + DAS12		1.18 (0.88 to 1.51)	14.51 (-10.09 to 32.94)
GRZ12 + ELB12		1.14 (0.98 to 1.46)	11.14 (-2.14 to 29.76)
GRZ12 + ELB12 + RBV12		1.07 (0.71 to 1.41)	6.12 (-24.68 to 26.98)
DCV12 + ASU12 + BEC12 + RBV12		1.17 (0.97 to 1.50)	14.01 (-2.45 to 32.17)
DCV12 + ASU12 + BEC12		1.13 (0.99 to 1.44)	10.46 (-1.07 to 28.54)
GRZ12 + ELB12 (50 mg q.d.)		1.13 (0.82 to 1.46)	10.64 (-15.71 to 29.85)
GRZ18 + ELB18 (50 mg q.d.)		1.11 (0.67 to 1.44)	8.93 (-27.79 to 29.24)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.65 (0.00 to 1.37)	-28.16 (-86.87 to 26.01)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.13 (0.75 to 1.46)	10.45 (-20.92 to 30.36)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.15 (0.75 to 1.48)	12.45 (-20.96 to 31.70)
SOF12 + SIM12 + RBV12	SOF24 + RBV (low dose) 24	1.91 (0.62 to 4.09)	43.16 (-19.55 to 72.48)
SOF12 + RBV12		1.73 (1.20 to 3.14)	34.18 (10.80 to 57.45)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.08 (1.34 to 4.25)	49.93 (24.18 to 73.08)
DCV24 + ASU24		1.88 (1.18 to 3.90)	40.53 (12.74 to 65.35)
DCV12 + SOF12		2.01 (1.23 to 4.22)	46.98 (14.96 to 72.92)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12		2.06 (1.28 to 4.26)	49.66 (18.25 to 73.50)
GRZ12 + ELB12		2.01 (1.28 to 4.19)	46.65 (19.90 to 71.41)
GRZ12 + ELB12 + RBV12		1.87 (1.06 to 4.03)	40.39 (3.41 to 69.77)
DCV12 + ASU12 + BEC12 + RBV12		2.06 (1.32 to 4.26)	49.06 (22.50 to 74.05)
DCV12 + ASU12 + BEC12		2.00 (1.28 to 4.12)	46.15 (19.96 to 70.02)
GRZ12 + ELB12 (50 mg q.d.)		1.96 (1.19 to 4.21)	44.47 (12.87 to 72.84)
GRZ18 + ELB18 (50 mg q.d.)		1.90 (1.01 to 4.09)	42.50 (0.31 to 72.13)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		1.12 (0.01 to 3.46)	5.65 (-61.39 to 67.62)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.96 (1.12 to 4.14)	44.74 (7.64 to 72.46)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.99 (1.19 to 4.21)	46.16 (11.78 to 74.22)
SOF12 + RBV12	SOF12 + SIM12 + RBV12	0.92 (0.54 to 2.72)	-7.81 (-44.47 to 57.10)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.03 (0.94 to 2.99)	2.96 (-5.53 to 64.03)
DCV24 + ASU24		0.93 (0.81 to 2.71)	-6.15 (-18.46 to 55.62)
DCV12 + SOF12		1.02 (0.75 to 2.91)	1.48 (-23.83 to 61.21)
PAR/RIT12 + OMB12 + DAS12		1.04 (0.79 to 3.01)	3.28 (-20.34 to 65.20)
GRZ12 + ELB12		1.00 (0.88 to 2.90)	0.08 (-11.47 to 61.05)
GRZ12 + ELB12 + RBV12		0.96 (0.65 to 2.61)	-3.59 (-33.20 to 53.68)
DCV12 + ASU12 + BEC12 + RBV12		1.03 (0.87 to 2.98)	3.14 (-12.73 to 64.25)
DCV12 + ASU12 + BEC12		0.99 (0.90 to 2.86)	-0.71 (-9.91 to 60.28)
GRZ12 + ELB12 (50 mg q.d.)		0.99 (0.75 to 2.80)	-0.55 (-24.01 to 59.53)
GRZ18 + ELB18 (50 mg q.d.)		0.99 (0.58 to 2.83)	-1.35 (-39.04 to 59.86)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.62 (0.00 to 2.08)	-32.82 (-97.31 to 43.12)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.00 (0.67 to 2.85)	-0.38 (-30.75 to 60.66)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.02 (0.67 to 2.88)	1.49 (-31.26 to 62.00)
PAR/RIT12 + OMB12 + DAS12 + RBV12	SOF12 + RBV12	1.15 (0.99 to 1.91)	12.37 (-1.43 to 45.63)
DCV24 + ASU24		1.04 (0.86 to 1.75)	3.07 (-13.45 to 37.54)
DCV12 + SOF12		1.12 (0.84 to 1.90)	10.28 (-14.40 to 45.89)
PAR/RIT12 + OMB12 + DAS12		1.14 (0.90 to 1.90)	12.23 (-8.36 to 46.21)
GRZ12 + ELB12		1.11 (0.93 to 1.88)	9.18 (-6.90 to 43.85)
GRZ12 + ELB12 + RBV12		1.05 (0.68 to 1.76)	4.22 (-28.24 to 38.92)
DCV12 + ASU12 + BEC12 + RBV12		1.14 (0.95 to 1.92)	11.62 (-4.88 to 46.25)
DCV12 + ASU12 + BEC12		1.10 (0.94 to 1.86)	8.58 (-5.65 to 42.90)
GRZ12 + ELB12 (50 mg q.d.)		1.09 (0.80 to 1.90)	7.99 (-17.72 to 45.16)
GRZ18 + ELB18 (50 mg q.d.)		1.08 (0.63 to 1.86)	6.70 (-32.37 to 43.95)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.66 (0.00 to 1.61)	-27.89 (-91.17 to 35.50)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.09 (0.73 to 1.89)	7.82 (-23.60 to 44.90)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.11 (0.74 to 1.92)	9.76 (-22.28 to 46.25)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.90 (0.80 to 0.98)	-9.30 (-19.01 to -2.24)
DCV12 + SOF12		0.99 (0.74 to 1.07)	-0.82 (-24.58 to 6.06)
PAR/RIT12 + OMB12 + DAS12		1.01 (0.77 to 1.07)	1.15 (-22.58 to 6.57)
GRZ12 + ELB12		0.97 (0.87 to 1.04)	-2.75 (-12.45 to 3.51)
GRZ12 + ELB12 + RBV12		0.92 (0.61 to 1.03)	-7.72 (-37.73 to 3.04)
DCV12 + ASU12 + BEC12 + RBV12		1.00 (0.86 to 1.07)	0.38 (-13.98 to 6.07)
DCV12 + ASU12 + BEC12		0.96 (0.89 to 1.02)	-3.62 (-10.22 to 1.96)
GRZ12 + ELB12 (50 mg q.d.)		0.97 (0.72 to 1.05)	-3.24 (-26.76 to 4.63)
GRZ18 + ELB18 (50 mg q.d.)		0.96 (0.56 to 1.05)	-4.13 (-42.63 to 4.81)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.55 (0.00 to 1.05)	-43.00 (-96.81 to 4.79)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.97 (0.64 to 1.05)	-3.04 (-34.65 to 5.01)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.99 (0.65 to 1.07)	-0.65 (-33.58 to 6.38)
DCV12 + SOF12	DCV24 + ASU24	1.09 (0.81 to 1.25)	8.21 (-16.41 to 19.28)
PAR/RIT12 + OMB12 + DAS12		1.12 (0.85 to 1.26)	10.20 (-13.56 to 20.08)
GRZ12 + ELB12		1.08 (0.95 to 1.22)	6.53 (-4.28 to 16.92)
GRZ12 + ELB12 + RBV12		1.02 (0.68 to 1.19)	1.52 (-28.24 to 15.19)
DCV12 + ASU12 + BEC12 + RBV12		1.11 (0.94 to 1.25)	9.42 (-5.52 to 19.54)
DCV12 + ASU12 + BEC12		1.07 (0.97 to 1.20)	5.65 (-2.28 to 15.47)
GRZ12 + ELB12 (50 mg q.d.)		1.07 (0.79 to 1.22)	6.04 (-18.29 to 17.74)
GRZ18 + ELB18 (50 mg q.d.)		1.06 (0.62 to 1.22)	5.28 (-33.51 to 17.59)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.61 (0.00 to 1.20)	-33.66 (-88.71 to 16.24)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.07 (0.70 to 1.23)	6.09 (-26.34 to 18.15)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.09 (0.71 to 1.25)	8.26 (-25.50 to 19.28)
PAR/RIT12 + OMB12 + DAS12	DCV12 + SOF12	1.02 (0.76 to 1.37)	1.52 (-23.00 to 26.25)
GRZ12 + ELB12		0.98 (0.87 to 1.33)	-1.95 (-12.68 to 23.41)
GRZ12 + ELB12 + RBV12		0.94 (0.62 to 1.26)	-6.09 (-36.47 to 19.37)
DCV12 + ASU12 + BEC12 + RBV12		1.01 (0.86 to 1.37)	0.90 (-13.89 to 26.07)
DCV12 + ASU12 + BEC12		0.97 (0.89 to 1.31)	-2.85 (-10.64 to 21.84)
GRZ12 + ELB12 (50 mg q.d.)		0.98 (0.73 to 1.33)	-2.19 (-26.59 to 23.65)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ18 + ELB18 (50 mg q.d.)		0.97 (0.57 to 1.34)	-2.83 (-41.21 to 24.13)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.57 (0.00 to 1.20)	-39.94 (-97.41 to 15.97)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.98 (0.65 to 1.32)	-1.76 (-33.09 to 22.95)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.00 (0.66 to 1.37)	-0.17 (-32.32 to 26.01)
GRZ12 + ELB12	PAR/RIT12 + OMB12 + DAS12	0.96 (0.87 to 1.25)	-3.62 (-13.14 to 18.32)
GRZ12 + ELB12 + RBV12		0.91 (0.62 to 1.18)	-8.30 (-36.65 to 13.74)
DCV12 + ASU12 + BEC12 + RBV12		0.99 (0.85 to 1.28)	-0.56 (-14.36 to 21.08)
DCV12 + ASU12 + BEC12		0.95 (0.89 to 1.26)	-4.73 (-11.29 to 18.81)
GRZ12 + ELB12 (50 mg q.d.)		0.96 (0.73 to 1.24)	-3.78 (-26.73 to 17.98)
GRZ18 + ELB18 (50 mg q.d.)		0.95 (0.56 to 1.22)	-4.49 (-43.01 to 17.39)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.56 (0.00 to 1.11)	-42.03 (-98.26 to 9.68)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.97 (0.64 to 1.24)	-3.37 (-34.73 to 18.35)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.98 (0.65 to 1.28)	-1.59 (-33.86 to 21.38)
GRZ12 + ELB12 + RBV12	GRZ12 + ELB12	0.95 (0.63 to 1.09)	-4.76 (-34.40 to 7.94)
DCV12 + ASU12 + BEC12 + RBV12		1.03 (0.88 to 1.15)	2.86 (-11.21 to 12.42)
DCV12 + ASU12 + BEC12		0.99 (0.91 to 1.10)	-0.89 (-8.29 to 8.83)
GRZ12 + ELB12 (50 mg q.d.)		1.00 (0.75 to 1.12)	-0.44 (-23.75 to 10.53)
GRZ18 + ELB18 (50 mg q.d.)		0.99 (0.58 to 1.12)	-1.36 (-39.28 to 10.39)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.57 (0.00 to 1.11)	-39.93 (-94.78 to 9.48)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.00 (0.66 to 1.12)	-0.17 (-31.86 to 10.68)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.02 (0.67 to 1.14)	1.91 (-30.81 to 12.27)
DCV12 + ASU12 + BEC12 + RBV12	GRZ12 + ELB12 + RBV12	1.08 (0.90 to 1.64)	7.47 (-9.48 to 37.80)
DCV12 + ASU12 + BEC12		1.04 (0.93 to 1.58)	3.92 (-6.67 to 34.11)
GRZ12 + ELB12 (50 mg q.d.)		1.04 (0.87 to 1.41)	3.78 (-11.22 to 25.00)
GRZ18 + ELB18 (50 mg q.d.)		1.04 (0.66 to 1.43)	3.18 (-29.67 to 27.48)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.61 (0.00 to 1.36)	-33.33 (-92.99 to 25.69)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.04 (0.74 to 1.46)	3.84 (-22.40 to 28.78)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.07 (0.72 to 1.54)	5.89 (-24.70 to 32.68)
DCV12 + ASU12 + BEC12	DCV12 + ASU12 + BEC12 + RBV12	0.96 (0.90 to 1.11)	-3.85 (-9.96 to 9.37)
GRZ12 + ELB12 (50 mg q.d.)		0.97 (0.72 to 1.13)	-3.03 (-26.95 to 10.89)
GRZ18 + ELB18 (50 mg q.d.)		0.96 (0.56 to 1.13)	-3.90 (-41.75 to 10.79)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.56 (0.00 to 1.09)	-42.23 (-97.73 to 8.38)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.97 (0.65 to 1.13)	-2.70 (-33.33 to 10.69)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.99 (0.66 to 1.15)	-0.95 (-32.87 to 12.82)
GRZ12 + ELB12 (50 mg q.d.)	DCV12 + ASU12 + BEC12	1.01 (0.75 to 1.10)	0.49 (-23.40 to 8.98)
GRZ18 + ELB18 (50 mg q.d.)		1.00 (0.58 to 1.10)	-0.34 (-38.98 to 8.93)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.58 (0.00 to 1.10)	-39.18 (-93.43 to 8.84)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.01 (0.66 to 1.11)	0.64 (-31.16 to 9.37)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.03 (0.68 to 1.12)	2.89 (-29.30 to 10.38)
GRZ18 + ELB18 (50 mg q.d.)	GRZ12 + ELB12 (50 mg q.d.)	0.99 (0.67 to 1.14)	-0.96 (-27.73 to 11.34)
GRZ8 + ELB8 (50 mg q.d.) + RBV8		0.58 (0.00 to 1.23)	-37.92 (-95.73 to 17.65)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.00 (0.78 to 1.15)	0.25 (-18.64 to 11.87)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.02 (0.75 to 1.25)	1.55 (-21.70 to 18.97)
GRZ8 + ELB8 (50 mg q.d.) + RBV8	GRZ18 + ELB18 (50 mg q.d.)	0.60 (0.00 to 1.44)	-34.76 (-96.05 to 28.34)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.01 (0.82 to 1.46)	1.00 (-15.44 to 27.29)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.03 (0.82 to 1.57)	2.36 (-15.63 to 32.48)
GRZ12 + ELB12 (50 mg q.d.) + RBV12	GRZ8 + ELB8 (50 mg q.d.) + RBV8	1.70 (0.78 to 401.30)	37.11 (-21.28 to 96.25)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.74 (0.79 to 406.90)	39.21 (-19.23 to 97.50)
GRZ18 + ELB18 (50 mg q.d.) + RBV18	GRZ12 + ELB12 (50 mg q.d.) + RBV12	1.02 (0.77 to 1.32)	1.52 (-19.80 to 22.02)
Random effect model	Residual deviance	80.61 vs. 87 data points	
	Deviance information criteria	463.014	
Fixed effect model	Residual deviance	80.74 vs. 87 data points	
	Deviance information criteria	461.479	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.